ACR: Inebilizumab Reduces Risk for Flares in IgG4-Related Disease

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 19, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Nov. 19, 2024 -- For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the likelihood of flare-free complete remission, according to a study published online Nov. 14 in the New England Journal of Medicine to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 14 to 19 in Washington, D.C.

John H. Stone, M.D., M.P.H., from Massachusetts General Hospital in Boston, and colleagues conducted a phase 3, multicenter, double-blind, randomized trial involving adults with active IgG4-related disease. A total of 135 participants were randomly assigned to receive inebilizumab (300-mg infusions on days 1 and 15 and week 26) or placebo (68 and 67 participants, respectively). In both groups, participants received identical glucocorticoid tapers.

The researchers found that flare risk was reduced with inebilizumab treatment: 10 and 60 percent of participants in the inebilizumab and placebo groups had at least one flare, respectively (hazard ratio, 0.13). A lower annualized flare rate was seen with inebilizumab than placebo (rate ratio, 0.14). Flare-free, treatment-free complete remission and flare-free, glucocorticoid-free complete remission occurred in more participants in the inebilizumab group than the placebo group (odds ratios, 4.68 and 4.96, respectively). During the treatment period, serious adverse events occurred in 18 and 9 percent of participants receiving inebilizumab and placebo, respectively.

"The magnitude and consistency of the efficacy results suggest inebilizumab as a treatment option for patients with IgG4-related disease," the authors write.

The study was funded by Amgen, the manufacturer of inebilizumab.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-11-20 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords